Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808223 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2 study of Psoriasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT00808223: Completed Phase 2 study of Psoriasis, sponsored by Astellas Pharma.
NCT00808223 is a Phase 2 study of Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 30 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00808223, a Phase 2 study of Psoriasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
Conditions Studied
Interventions
- BIOLOGICAL alefacept
Study Locations (5)
Other
- First Municipal Hospital for Active Treatment - Sofia - Sofia
- Skin and STD Clinical Centre - Riga
- Department of Dermatology No.17, Children Clinical Hospital - Riga
California
- Pediatric and Adolescent Dermatology - San Diego
Kentucky
- Physicians Skin Care, PLLC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT00808223 record still lists
NCT00808223 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which alefacept is the first listed.
NCT00808223 lists 5 locations in 3 states (Other, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00808223 about?
NCT00808223 is a clinical study titled "Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis". To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
What is the current status of trial NCT00808223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-04. Estimated completion is 2012-02.
What conditions does trial NCT00808223 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00808223?
The interventions under investigation include: alefacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00808223?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808223 being conducted?
This trial has 5 study locations across California, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00808223's enrollment target sits among peer trials
30 95th of 125 higher than 26 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia